EMA recommends authorisation of first RSV vaccine for infants
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Pfizer Europe’s Abrysvo ( EMA opinion on Abrysvo: https://bit.ly/45jVL7Z ), a vaccine to protect against disease caused by the respiratory syncytial virus (RSV). Abrysvo is the first RSV vaccine indicated for passive immunisation of infants from birth through […]
